<p>DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with αMT (250 mg/kg IP) and 1 h after αMT were challenged with single or multiple doses of a drug (interval between treatments is 1 h). L-DOPA itself (A) or in combination with carbidopa (B–D) effectively restored locomotion in DDD mice, as revealed by the significant effect of L-DOPA at doses 100 and 200 mg/kg IP, or combinations of L-DOPA/carbidopa at doses 20/20, 50/20, and 50/50 mg/kg, IP (analysis of total distance traveled for 1 h after each dose of the drug; <i>p</i> < 0.05, two-tailed Mann-Whitney <i>U</i> test versus respective values in saline-treated DDD mice; data not shown). Nonselective DA receptor agonists, apomorphine (E) at doses 2 an...
<p><b>(A)</b> At 8 and 10 months following initiation of BSSG exposure, animals displayed a time-dep...
Appearance of l-DOPA-induced dyskinesia (LID) represents a major limitation in the pharmacological t...
<p>DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with αMT ...
L-DOPA is the mainstay of treatment for Parkinson’s disease (PD). However, over time this drug can p...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...
D2 receptors have been studied in relation to therapeutic uses of dopaminergic drugs, and psychomoto...
Motor activity of mice acutely treated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,5,6-tetrahy...
Motor activity of mice acutely treated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,5,6-tetrahy...
We compared the ability of various dopamine (DA) uptake inhibitors to displace the in vivo striatal ...
Examined the locomotor stimulatory effects of the dopamine D-sub-1 receptor partial agonist SKF 3839...
Rodent models of L-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mec...
<p>The figure summarizes SKF81297-induced locomotion at (<b>A</b>) 0.5mg/kg and (<b>B</b>) 1mg/kg i....
L-DOPA-induced dyskinesia (LID) is a significant complication of dopamine replacement therapy in Par...
<p>DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with αMT ...
<p><b>(A)</b> At 8 and 10 months following initiation of BSSG exposure, animals displayed a time-dep...
Appearance of l-DOPA-induced dyskinesia (LID) represents a major limitation in the pharmacological t...
<p>DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with αMT ...
L-DOPA is the mainstay of treatment for Parkinson’s disease (PD). However, over time this drug can p...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...
D2 receptors have been studied in relation to therapeutic uses of dopaminergic drugs, and psychomoto...
Motor activity of mice acutely treated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,5,6-tetrahy...
Motor activity of mice acutely treated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,5,6-tetrahy...
We compared the ability of various dopamine (DA) uptake inhibitors to displace the in vivo striatal ...
Examined the locomotor stimulatory effects of the dopamine D-sub-1 receptor partial agonist SKF 3839...
Rodent models of L-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mec...
<p>The figure summarizes SKF81297-induced locomotion at (<b>A</b>) 0.5mg/kg and (<b>B</b>) 1mg/kg i....
L-DOPA-induced dyskinesia (LID) is a significant complication of dopamine replacement therapy in Par...
<p>DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with αMT ...
<p><b>(A)</b> At 8 and 10 months following initiation of BSSG exposure, animals displayed a time-dep...
Appearance of l-DOPA-induced dyskinesia (LID) represents a major limitation in the pharmacological t...
<p>DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with αMT ...